Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell LinesClaudia Fumarola, Pier Giorgio Petronini|Frontiers in Oncology|2019Cited by 48
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell linesRoberta Alfieri, Pier Giorgio Petronini|Molecular Cancer|2011Cited by 46
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell LinesGraziana Digiacomo, Pier Giorgio Petronini|Frontiers in Oncology|2020Cited by 31